CAMBRIDGE, Mass., Dec. 9, 2020 /PRNewswire/ -- Synlogic, Inc.
(Nasdaq: SYBX), a clinical stage company bringing the
transformative potential of synthetic biology to medicine, today
announced the appointment of Michael
Heffernan to its board of directors.
"We are delighted to welcome Mike to our Board," said Aoife
Brennan, M.B, Ch.B., Synlogic's President and Chief
Executive Officer. "His deep experience leading growing companies
as both an executive and a board member will be a tremendous asset
as our Synthetic Biotic portfolio progresses towards multiple
opportunities for clinical proof of concept in the new year. We
look forward to learning from his experience building companies
that change patients' lives."
Mr. Heffernan is a seasoned entrepreneur and biopharmaceutical
leader with over 25 years of experience building and leading
development stage and commercial companies. He is the Founder and
Chairman of the Board of Collegium Pharmaceutical where he served
as President and CEO until June 2018.
He co-founded Avenge Bio, an Immuno-Oncology company that he is
actively managing, and was previously CEO of Onset Dermatologics, a
dermatology company that he founded and spun out of Collegium to
create PreCision Dermatology, which was later sold to Valeant. Mr.
Heffernan held previous positions as co-founder and CEO of Clinical
Studies Ltd. and later served as CEO and Chairman of PhyMatrix
Corp. He earned his B.S. degree in Pharmacy from the University of Connecticut and began his career at
Eli Lilly and Company.
Mr. Heffernan serves on the board of directors of Akebia
Therapeutics, Inc. (AKBA), Trevi Therapeutics, Inc. (TRVI) and
Biohaven Pharmaceutical Holding Company Ltd. (BHVN). He previously
served on the board of directors of Keryx Biopharmaceuticals, Inc.,
Ocata Therapeutics, Inc., Cornerstone Therapeutics Inc., and
Veloxis Pharmaceuticals A/S.
"Synlogic has made significant progress this year across their
metabolic and immunomodulation programs," said Mr. Heffernan. "I am
thrilled to be joining at this pivotal stage as the company moves
forward into a data rich 2021, and I look forward to contributing
to Synlogic's future success."
Learn more about Synlogic's programs and pipeline by visiting
Synlogic™ is bringing the
transformative potential of synthetic biology to medicine. With a
premiere synthetic biology platform that leverages a reproducible,
modular approach to microbial engineering, Synlogic designs
Synthetic Biotic medicines that target validated underlying biology
to treat disease in new ways. Synlogic's proprietary pipeline
includes Synthetic Biotics for the treatment of metabolic disorders
including Phenylketonuria (PKU) and Enteric Hyperoxaluria (HOX).
The company is also building a portfolio of partner-able assets in
immunology and oncology.
This press release contains
"forward-looking statements" that involve substantial risks and
uncertainties for purposes of the safe harbor provided by the
Private Securities Litigation Reform Act of 1995. All statements,
other than statements of historical facts, included in this press
release regarding strategy, future operations, clinical development
plans, future financial position, future revenue, projected
expenses, prospects, plans and objectives of management are
forward-looking statements. In addition, when or if used in this
press release, the words "may," "could," "should," "anticipate,"
"believe," "estimate," "expect," "intend," "plan," "predict" and
similar expressions and their variants, as they relate to Synlogic
may identify forward-looking statements. Examples of
forward-looking statements, include, but are not limited to,
statements regarding the potential of Synlogic's platform to
develop therapeutics to address a wide range of diseases including:
cancer, inborn errors of metabolism, and inflammatory and
immune disorders; the future clinical development of Synthetic
Biotic medicines; the approach Synlogic is taking to discover and
develop novel therapeutics using synthetic biology; and the
expected timing of Synlogic's clinical trials and availability of
clinical trial data. Actual results could differ materially from
those contained in any forward-looking statement as a result of
various factors, including: the uncertainties inherent in the
clinical and preclinical development process; the ability
of Synlogic to protect its intellectual property rights;
and legislative, regulatory, political and economic developments,
as well as those risks identified under the heading "Risk Factors"
in Synlogic's filings with the SEC. The
forward-looking statements contained in this press release
reflect Synlogic's current views with respect to future
events. Synlogic anticipates that subsequent events and
developments will cause its views to change. However,
while Synlogic may elect to update these forward-looking
statements in the future, Synlogic specifically disclaims
any obligation to do so. These forward-looking statements should
not be relied upon as representing Synlogic's view as of any date
subsequent to the date hereof.
View original content to download
SOURCE Synlogic, Inc.